Summary of COVID-19 domperidone studies
Hide extended summaries
RCT 173 outpatients with mild-to-moderate COVID-19 showing no significant difference with domperidone versus placebo for viral clearance or symptom recovery.
Oct 2023, Annals of Medicine, https://www.tandfonline.com/doi/full/10.1080/07853890.2023.2268535, https://c19p.org/rabanalbasalo
1. Rabanal Basalo et al., A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care
173 patient domperidone early treatment RCT: 36% worse recovery (p=0.23) and 15% worse viral clearance (p=0.62).RCT 173 outpatients with mild-to-moderate COVID-19 showing no significant difference with domperidone versus placebo for viral clearance or symptom recovery.
Oct 2023, Annals of Medicine, https://www.tandfonline.com/doi/full/10.1080/07853890.2023.2268535, https://c19p.org/rabanalbasalo
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.